Skip to content
Hidehito HORINOUCHI· @HHorinouchi · X·· 19 hours agoScore45

#LCSM

Body

🆙#ESMO26 #LCSM Special Symposium
🔥SCLC: Can we finally tackle it?
🎯Emerging targets for SCLC: Are molecular classification and treatment selection going to help? (Incl. neversmorkers)
🎙️ @charlesrudin
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/29
@OncoAlert @Larvol @myESMO

167 views · 5 likes · 4 reposts · 0 replies

Source: Hidehito HORINOUCHI · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org